BraylinCAS# 6054-10-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 6054-10-0 | SDF | Download SDF |
| PubChem ID | 618370 | Appearance | Cryst. |
| Formula | C15H14O4 | M.Wt | 258.3 |
| Type of Compound | Coumarins | Storage | Desiccate at -20°C |
| Synonyms | Brayelin | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 6-methoxy-8,8-dimethylpyrano[2,3-f]chromen-2-one | ||
| SMILES | CC1(C=CC2=C3C(=CC(=C2O1)OC)C=CC(=O)O3)C | ||
| Standard InChIKey | UOFNVZWWIXXTMZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H14O4/c1-15(2)7-6-10-13-9(4-5-12(16)18-13)8-11(17-3)14(10)19-15/h4-8H,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Braylin has anti-inflammatory, antinociceptive and immunomodulatory effects, which possibly act through the glucocorticoid receptor activation and by inhibition of the transcriptional activity of NF-κB. 2. Braylin is a phosphodiesterase-4 inhibitor, it could represent an ideal prototype of glucocorticoid receptor ligand, able to induce synergic immunomodulatory effects. |
| Targets | IL Receptor | TNF-α | IFN-γ | NF-kB | TGF-β/Smad |
Braylin Dilution Calculator
Braylin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.8715 mL | 19.3573 mL | 38.7147 mL | 77.4293 mL | 96.7867 mL |
| 5 mM | 0.7743 mL | 3.8715 mL | 7.7429 mL | 15.4859 mL | 19.3573 mL |
| 10 mM | 0.3871 mL | 1.9357 mL | 3.8715 mL | 7.7429 mL | 9.6787 mL |
| 50 mM | 0.0774 mL | 0.3871 mL | 0.7743 mL | 1.5486 mL | 1.9357 mL |
| 100 mM | 0.0387 mL | 0.1936 mL | 0.3871 mL | 0.7743 mL | 0.9679 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Methyloleoside
Catalog No.:BCN8079
CAS No.:60539-23-3
- H-D-Thr-OMe.HCl
Catalog No.:BCC2675
CAS No.:60538-15-0
- Zimelidine dihydrochloride
Catalog No.:BCC7173
CAS No.:60525-15-7
- 5,6-Dihydropyridin-2(1H)-one
Catalog No.:BCN4013
CAS No.:6052-73-9
- Serpentinic acid
Catalog No.:BCN4616
CAS No.:605-14-1
- Pifithrin-β
Catalog No.:BCC5503
CAS No.:60477-34-1
- Cytisine Hydrochloride
Catalog No.:BCN8133
CAS No.:6047-01-4
- Cauloside F
Catalog No.:BCN3848
CAS No.:60451-47-0
- Neopetasitenine
Catalog No.:BCN2114
CAS No.:60409-51-0
- Cucurbitacin A
Catalog No.:BCN2468
CAS No.:6040-19-3
- Tombozine
Catalog No.:BCN4117
CAS No.:604-99-9
- Narcissoside
Catalog No.:BCN1263
CAS No.:604-80-8
- Olsalazine Sodium
Catalog No.:BCC3829
CAS No.:6054-98-4
- Gomisin D
Catalog No.:BCN2268
CAS No.:60546-10-3
- 1-Acetyltagitinin A
Catalog No.:BCN4119
CAS No.:60547-63-9
- P1075
Catalog No.:BCC7027
CAS No.:60559-98-0
- DCEBIO
Catalog No.:BCC7060
CAS No.:60563-36-2
- Tirandamycin B
Catalog No.:BCN1862
CAS No.:60587-14-6
- Pamabrom
Catalog No.:BCC1835
CAS No.:606-04-2
- 2,4'-Dihydroxybenzophenone
Catalog No.:BCN3358
CAS No.:606-12-2
- Toyocamycin
Catalog No.:BCC8047
CAS No.:606-58-6
- Cinnabarinic acid
Catalog No.:BCC7865
CAS No.:606-59-7
- Homopterocarpin
Catalog No.:BCN4615
CAS No.:606-91-7
- MK-0773
Catalog No.:BCC1754
CAS No.:606101-58-0
Vasorelaxing properties and bio-guided fractionation of Cedrelopsis grevei.[Pubmed:12624830]
Planta Med. 2003 Feb;69(2):179-81.
The activity-guided fractionation of the hydroalcoholic extract of trunk bark of Cedrelopsis grevei led to the isolation of five coumarins, norBraylin (1), methyl-O-cedrelopsin (2), cedrecoumarin A (3), scoparone (4) and Braylin (5) as a part of the constituents responsible for the vasorelaxing activity observed for the crude extract.
The anti-inflammatory and immunomodulatory potential of braylin: Pharmacological properties and mechanisms by in silico, in vitro and in vivo approaches.[Pubmed:28594906]
PLoS One. 2017 Jun 8;12(6):e0179174.
Braylin belongs to the group of natural coumarins, a group of compounds with a wide range of pharmacological properties. Here we characterized the pharmacological properties of Braylin in vitro, in silico and in vivo in models of inflammatory/immune responses. In in vitro assays, Braylin exhibited concentration-dependent suppressive activity on activated macrophages. Braylin (10-40 muM) reduced the production of nitrite, IL-1beta, TNF-alpha and IL-6 by J774 cells or peritoneal exudate macrophages stimulated with LPS and IFN-gamma. Molecular docking calculations suggested that Braylin present an interaction pose to act as a glucocorticoid receptor ligand. Corroborating this idea, the inhibitory effect of Braylin on macrophages was prevented by RU486, a glucocorticoid receptor antagonist. Furthermore, treatment with Braylin strongly reduced the NF-kappaB-dependent transcriptional activity on RAW 264.7 cells. Using the complete Freund's adjuvant (CFA)-induced paw inflammation model in mice, the pharmacological properties of Braylin were demonstrated in vivo. Braylin (12.5-100 mg/kg) produced dose-related antinociceptive and antiedematogenic effects on CFA model. Braylin did not produce antinociception on the tail flick and hot plate tests in mice, suggesting that Braylin-induced antinociception is not a centrally-mediated action. Braylin exhibited immunomodulatory properties on the CFA model, inhibiting the production of pro-inflammatory cytokines IL-1beta, TNF-alpha and IL-6, while increased the anti-inflammatory cytokine TGF-beta. Our results show, for the first time, anti-inflammatory, antinociceptive and immunomodulatory effects of Braylin, which possibly act through the glucocorticoid receptor activation and by inhibition of the transcriptional activity of NF-kappaB. Because Braylin is a phosphodiesterase-4 inhibitor, this coumarin could represent an ideal prototype of glucocorticoid receptor ligand, able to induce synergic immunomodulatory effects.
